Fast weight loss, although useful for resetting excess fat, often leads to undesirable and serious consequences: loss of muscle and bone mass. Such a decrease can increase the risk of osteoporosis - a condition in which the bones become fragile and more prone to fractures. Researchers from the University of Orchus in Denmark studied the drug originally designed to combat muscle depletion to combat such consequences, writes.
The focus. Technology has its own Telegram channel. Subscribe so as not to miss the latest and most exciting news from the world of science!
Doctoral student Frederick Spirit Bromer and post -class researcher Andreas Lodberg discovered that the drug called Bimagrumab not only retains muscle mass, but also increases the density of bones. Their study, published in the Journal of Cachexia, Sarcopenia and Muscle, allowed them to suggest that it can become a promising auxiliary tool for people undergoing weight reduction.
Bimagrumab acts by inhibiting the type-2B activine receptor, a protein that regulates muscle growth. In addition to muscle-preserving properties, the drug demonstrated the ability to reduce the amount of fat in the body. Such a double effect makes it a potential drug of a new generation to reduce weight without significant side effects.
Given the forecasts, according to which by 2035 more than two billion people around the world will be classified as overweight, understanding and mitigation of side effects of drugs to reduce weight is paramount importance. Lodberg noted: "
The study showed that Bimagrumab slightly increases the content of calcium in the bones and promotes the formation of a new bone, especially in the cortical layer of long bones. A significant accumulation of bone tissue was also observed around the femoral head - a place often exposed to fractures in the elderly. These data indicate that the drug can provide protection against bone density loss associated with a rapid weight loss, the authors say.
However, security profiles are crucial when considering new therapeutic means. Although some drugs affecting similar paths were associated with an increase in the production of red blood cells and an increased risk of blood clots, in the study, Bimagrumab did not show similar effects. But, as Lodberg warns, "
Consequently, scientists still need further research to completely find out both the advantages and potential risks of prolonged use of bimarumabas for such purposes. Currently, the drug passes the 2nd phase of clinical trials to assess its effectiveness and safety in people. Despite promising results, only comprehensive clinical studies will determine its suitability as a standard means to prevent muscle and bone loss during therapy to reduce weight.
Bimagrumab is an important and promising potential solution to the problem of muscle and bone mass loss associated with a rapid weight loss, especially if clinical trials confirm its efficiency and safety. Since the level of obesity continues to grow all over the world, such innovations in the treatment of weight loss are necessary so that people can achieve a healthier physique without prejudice to the integrity of their musculoskeletal system.
Previously, Focus wrote that science posed an end to the question of fat and low -fat milk.
New studies have turned all our strengthened concepts about the benefits and dangers of dairy products, trying to facilitate a difficult choice in favor of a particular product.
Focus also wrote about how obesity irreversibly changes the brain. Obesity changes the sensors of the brain that are responsible for satisfaction from food, causing, possibly, the constant state of "
Important! This article is based on the latest scientific and medical research and does not contradict it. The text is exclusively informational in nature and does not contain medical advice. To establish a diagnosis, be sure to consult a doctor.